Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Propentofylline for dementia.

M Frampton1, R J Harvey, V Kirchner

  • 14 Edwin Terrace, Mellifont Avenue, Dun Laoire, Co. Dublin, Ireland. maria.frampton@virgin.net

The Cochrane Database of Systematic Reviews
|June 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Left-lateral laparotomy using a dorsoventral incision for unilateral ovariohysterectomy in free-ranging African lions (<i>Panthera leo</i>).

Journal of the South African Veterinary Association·2025
Same author

Operation Sahel: translocation and reintroduction of West African giraffe (<i>Giraffa camelopardalis peralta</i>) in Niger.

Journal of the South African Veterinary Association·2025
Same author

Algorithm for the Management of Primary Diffuse Chronic Rhinosinusitis.

Allergy·2024
Same author

Immobilisation protocols for wild giraffe <i>(Giraffa spp.)</i>- a review.

Journal of the South African Veterinary Association·2024
Same author

Consensus criteria for chronic rhinosinusitis disease control: an international Delphi Study.

Rhinology·2023
Same author

Protocolized screening and detection of occult alcohol use before and after liver transplant: Lessons learned from a quality improvement initiative.

Clinical transplantation·2023
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Propentofylline shows potential benefits for dementia patients, improving cognition, daily living, and global function. However, limited data and unpublished studies hinder a complete efficacy assessment.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Trials

Background:

  • Propentofylline is a novel agent for dementia, crossing the blood-brain barrier.
  • It inhibits adenosine uptake and phosphodiesterase, reducing free radicals and microglial activation.
  • Its mechanism suggests a disease-modifying potential beyond symptomatic treatment for inflammatory processes in dementia.

Purpose of the Study:

  • To determine the clinical efficacy and safety of propentofylline in individuals with dementia.
  • To evaluate propentofylline's impact on cognitive function, disease severity, and daily living activities.

Main Methods:

  • Systematic review of unconfounded double-blind randomized controlled trials.
  • Searched the Cochrane Dementia and Cognitive Improvement Group register.

Related Experiment Videos

  • Included trials compared propentofylline against placebo or other treatments.

    • Main Results:

    • Propentofylline demonstrated statistically significant improvements in cognition (MMSE) at 12 months.
    • Improvements were noted in dementia severity (CGI) and Activities of Daily Living (NAB) at various time points.
    • Global assessment (CGI) showed significant benefits at 3 months, but not later; dropouts favored placebo.

    Conclusions:

    • Limited evidence suggests propentofylline may benefit cognition, global function, and daily living in Alzheimer's and vascular dementia.
    • The review's scope was significantly limited by unpublished data from 1200 patients and the manufacturer's non-cooperation.
    • Further comprehensive studies are needed to fully ascertain propentofylline's efficacy and safety profile.